授乳期における5-メチルテトラヒドロ葉酸補給の母体健康と一炭素代謝への影響 (OCMS)
授乳期における5-メチルテトラヒドロ葉酸補給の母体健康および一炭素代謝への影響
This double-blind, randomized, placebo-controlled parallel trial evaluates the effects of maternal 5-methyltetrahydrofolate (5-MTHF) supplementation during breastfeeding. Thirty-six lactating mother-infant dyads will be randomized (1:1) to receive 5-MTHF or placebo for 6 weeks, stratified by infant sex and mode of delivery. Tolerability and adverse events will be monitored.
Pre- and post-intervention assessments include breast milk one-carbon metabolites and oligosaccharides; maternal plasma one-carbon metabolites and metabolic health markers. Maternal mental health will be evaluated using the SCL-90-R questionnaire. A follow-up visit at 4 months will reassess infant anthropometry and microbiome outcomes.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Carles Lerin, PhD
- 電話番号:(+34) 93 600 97 51
- メール:carles.lerin@sjd.es
研究連絡先のバックアップ
- 名前:Marta Ramon Krauel, MD PhD
- 電話番号:Ext. 71263 (+34) 93 280 40 00
- メール:marta.ramon@sjd.es
研究場所
-
-
Barcelona
-
Barcelona、Barcelona、スペイン、08950
- 募集
- Hospital Sant Joan de Deu
-
コンタクト:
- Carles Lerin, PhD
- 電話番号:(+34) 93 600 97 51
- メール:carles.lerin@sjd.es
-
Barcelona、Barcelona、スペイン、08950
- まだ募集していません
- Hospital Sant Joan de Déu
-
コンタクト:
- Carles Lerin, PhD
- 電話番号:936009751 Spain
- メール:carles.lerin@sjd.es
-
コンタクト:
- Carles Lerin
- 電話番号:601106790 Spain
- メール:carleslerin@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Maternal age between 18 and 42 years
- Gestational age at birth ≥ 37 weeks.
- Exclusive breastfeeding at enrollment.
- Infant age 0-1 months
Exclusion Criteria:
- Multiple pregnancy
- Presence of disease or malformations in the infant.
- Weight-Standard Deviation Score < -1 at enrollment.
- Use of folate-containing multivitamin supplements during breastfeeding
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:Placebo
Placebo |
Matching placebo administered daily for 6 weeks during lactation. |
|
実験的:5-MTHF Supplementation
Dietary Supplement (5-MTHF) |
Oral supplementation with 5-MTHF (800 µg) administered daily for 6 weeks during lactation. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of Adverse Events
時間枠:Baseline, 6 weeks, 4 months
|
Treatment safety and tolerability will be evaluated by assessing differences in the incidence of potential adverse events between groups, focusing on gastrointestinal symptoms. |
Baseline, 6 weeks, 4 months
|
|
Change in breast milk 5-MTHF concentration
時間枠:Baseline, 6 weeks
|
Change in breast milk 5-MTHF concentration measured with liquid chromatography coupled to mass spectrometry (LC-MS) from Baseline to 6 weeks. |
Baseline, 6 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in plasma 5-MTHF concentration
時間枠:Baseline, 6 weeks
|
Change in maternal plasma 5-MTHF concentration measured with liquid chromatography coupled to mass spectrometry (LC-MS) from Baseline to 6 weeks. |
Baseline, 6 weeks
|
|
Change in breast milk one-carbon metabolite concentration
時間枠:Baseline, 6 weeks
|
Change in breast milk one-carbon-related metabolites (choline, methionine, SAM, SAH, homocysteine, cystathionine, folic acid, betaine) from Baseline to 6 weeks. |
Baseline, 6 weeks
|
|
Change in plasma one-carbon metabolite concentration
時間枠:Baseline, 6 weeks
|
Change in plasma one-carbon-related metabolites (choline, methionine, SAM, SAH, homocysteine, cystathionine, folic acid, betaine) from Baseline to 6 weeks. |
Baseline, 6 weeks
|
|
Change in Human Milk Oligosaccharide (HMO) concentration
時間枠:Baseline, 6 weeks
|
Change in HMO concentrations between Baseline and 6 weeks |
Baseline, 6 weeks
|
|
Change in Maternal Plasma Glucose Concentration
時間枠:Baseline, 6 weeks
|
Change in maternal blood glucose levels between baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Maternal Plasma Glycated Hemoglobin (HbA1c) Concentration
時間枠:Baseline, 6 weeks
|
Change in maternal blood glycated hemoglobin (HbA1c) between baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Maternal Plasma Insulin Concentration
時間枠:Baseline, 6 weeks
|
Change in maternal blood insulin levels between Baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Maternal Plasma Triglyceride (TAG) Concentration
時間枠:Baseline, 6 weeks
|
Change in maternal blood triglyceride (TAG) levels between baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Maternal Blood Total Cholesterol Concentration
時間枠:Baseline, 6 weeks
|
Change in maternal blood total Cholesterol levels between baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Maternal Blood LDL Cholesterol Concentration
時間枠:Baseline, 6 weeks
|
Change in maternal low-density lipoprotein (LDL) cholesterol levels between baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Maternal Blood HDL Cholesterol Concentration
時間枠:Baseline, 6 weeks
|
Change in maternal high-density lipoprotein (HDL) cholesterol levels between baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Maternal Blood Alanine Aminotransferase (ALT) Levels
時間枠:Baseline, 6 weeks
|
Change in maternal alanine aminotransferase (ALT) levels between baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Maternal Blood Aspartate Aminotransferase (AST) Levels
時間枠:Baseline, 6 weeks
|
Change in maternal aspartate aminotransferase (AST) levels between baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Maternal Blood Gamma-Glutamyl Transferase (GGT) Levels
時間枠:Baseline, 6 weeks
|
Change in maternal gamma-glutamyl transferase (GGT) levels between baseline and 6 weeks. |
Baseline, 6 weeks
|
|
Change in Symptom Checklist-90-Revised (SCL-90-R) scale
時間枠:Baseline, 3 weeks
|
The SCL-90-R is a 90-item self-report questionnaire assessing psychological symptoms over the past week, with a range of 0-90 across 9 dimenions: Somatization, Obsessive-compulsive, Interpersonal sensitivity, Depression, Anxiety, Hostility, Phobic anxiety, Paranoid ideation, Psychoticism. Higher scores indicate worse outcome. |
Baseline, 3 weeks
|
|
Change in infant BMI z-score
時間枠:Baseline, 6 weeks
|
We will measure infant body weight, length, and head circumference to calculate BMI z-scores according to WHO growth standards, and changes between baseline, 6 weeks and 4 months will be assessed. |
Baseline, 6 weeks
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Maternal and infant gut microbiome composition
時間枠:Baseline, 6 weeks
|
Bacterial DNA will be isolated from infant and maternal fecal samples and sequenced to obtain microbiome composition. |
Baseline, 6 weeks
|
|
Maternal plasma and breast milk metabolomic profile
時間枠:Baselina, 6 weeks
|
The metabolomic profile will be obtained with the Biocrates Quant 1000 kit from plasma and breast milk samples. |
Baselina, 6 weeks
|
|
Milk imprinted protein levels
時間枠:Baseline, 6 weeks
|
Imprinted proteins in human milk samples will be analyzed by ELISA. |
Baseline, 6 weeks
|
協力者と研究者
捜査官
- 主任研究者:Carles Lerin, PhD、Fundació Sant Joan de Déu
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- PIC-143-25
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。